Zusammenfassung
Die perkutane Strahlentherapie ist eine wirksame Maßnahme zur Reduktion der lokalen inflammatorischen Reaktion sowie zur Inaktivierung proliferativer Eigenschaften des Tumors. Daher verfügt sie über eine messbare Effektivität bei Schmerzen, die durch Knochenmetastasen hervorgerufen werden (Adamietz u. Diel 2003, Arcangeli et al. 1998, Blum et al. 2003).
Knochenmetastasen entstehen durch hämatogene Tumorzelldissemination in das Knochenmark und sind eigentlich Metastasen des Knochenmarkes. Die dort wachsenden Tumorzellen können die Skelett- und Calciumhomöostase stören und sekundäre Knochenveränderungen hervorrufen, die als Tumorosteopathien bezeichnet werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
■ Zu 17.1
Adamietz IA, Diel IJ (2003) Bisphosphonate. Onkologe 9:495–509
Adamietz IA, Schneider O, Müller RP (2002) Results of a nationwide survey on radiotherapy of bone metastases in Germany. Strahlenther Onkol 178:531–536
Algur E, Macklis RM, Hafeli UO (2005) Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61:535–542
Arcangeli G, Giovinazzo G, Saracino B, et al. (1998) Radiation therapy in the management of symptomatic bone metastases:the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42:1119–1126
Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:1468–1472
Blum RH, Novetsky D, Shasha D, et al. (2003) The multidisciplinary approach to bone metastases. Oncology (Williston Park) 17:845–857; discussion 862–843, 867
Bone-Trial-Working-Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain:randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52:111–121
Böttcher HD, Adamietz IA (1997) Klinik der Skelettmetastasen. Zuckschwerdt, München Bern Wien New York
Chow E, Zeng L, Salvo N, et al. (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 24:112–124
Coleman R, Gnant M (2009) New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 3:213–218
Dempster DW, Lambing CL, Kostenuik PJ, et al. (2012). Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis:a review of preclinical and clinical data. Clin Ther 34 :521–536
Enright K, Clemons M, Chow E (2004) Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer 12:48–52
Expert Panel On Radiation Oncology–Bone Metastases, Lutz ST, Lo SS, et al. (2012) Appropriateness Criteria® non–spine bone metastases. J Palliat Med 15:521–526
Gnant M (2009) Bisphosphonates in the prevention of disease recurrence:current results and ongoing trials. Curr Cancer Drug Targets 9:824–833
Henry DH, Costa L, Goldwasser F, et al. (2001) Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132
Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321–327
Hoskin PJ, Price P, Easton D, et al. (1992) A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23:74–78.
Huisman M, van den Bosch MA, Wijlemans JW, et al. (2012) Effectiveness of reirradiation for painful bone metastases:a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 84:8–14
Kagan AR, Rose CM, Bedwinek JM, et al. (2000) Bone metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 215:1077–1104.
Kijima T, Fujii Y, Suyama T, et al. (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624.
Koswig S, Budach V (1999) Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10mal 3 Gy vs. 1mal 8 Gy). Strahlenther Onkol 175:500–508
Koswig S, Buchali A, Bohmer D, et al. (1999) Palliative Strahlentherapie von Knochenmetastasen. Eine retrospektive Analyse von 176 Patienten. Strahlenther Onkol 175:509–514
Lutz S, Berk L, Chang E, et al. (2011) Palliative radiotherapy for bone metastases:an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phy. 79:965–976
Mercadante S (2006) Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer 14:967–969
Mercadante S, Fulfaro F (2007) Management of painful bone metastases. Curr Opin Oncol 19:308–314
Ratanatharathorn V, Powers WE, Moss WT, et al. (1999) Bone metastasis:review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 44:1–18
Rieden K, Adolph J, Lellig U, et al. (1989a) Strahlentherapeutischer Effekt bei knochenmetastasen in Abhängigkeit von der Metastasenhäufig, Metastasenlokalisation und der Histologie des Primärtumors. Strahlenther Onkol 165:380–385
Rieden K, Mende U, Adolph J, et al. (1989b) Akzelerierte Bestrahlung von Knochenmetastasen. Strahlenther Onkol 165:23–27
Saad F (2006) Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 20:947–963
Saad F (2008) New research findings on zoledronic acid:survival, pain, and anti-tumour effects. Cancer Treat Rev 34:183–192
Saad F, Abrahamsson PA, Miller K (2009) Preserving bone health in patients with hormone-sensitive prostate cancer:the role of bisphosphonates. BJU Int 104:1573–1579
Salazar OM, DaMotta NW, Bridgman SM, et al. (1996) Fractionated halfbody irradiation for pain palliation in widely metastatic cancers:comparison with single dose. Int J Radiat Oncol Biol Phys 36:49–60
Salazar OM, Sandhu T, da Motta NW, et al. (2001) Fractionated halfbody irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease:a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 50:765–775
Sauer N, Leising D, Wild B, et al. (2006) Der Einfluss palliativer Strahlentherapie auf Schmerz und Lebensqualitat bei Patienten mit Knochenmetastasen. Strahlenther Onkol 182:550–556
Souchon R, Wenz F, Sedlmayer F, et al. (2009) DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer:bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol. 185:417–424
Stopeck AT, Lipton A, Body JJ, et al. (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blinded study. J Clin Oncol 28:5132–5239
Szumacher E, Llewellyn-Thomas H, Franssen E, et al. (2005) Treatment of bone metastases with palliative radiotherapy:patients’ treatment preferences. Int J Radiat Oncol Biol Phys 61:1473–1481
Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases:final results of the Study by the Radiation Therapy Oncology Group. Cancer 50:893–899
Tsuya A, Kurata T, Tamura K, et al. (2007) Skeletal metastases in non-small cell lung cancer:a retrospective study. Lung Cancer 57:229–232
Ural AU, Avcu F, Candir M, et al. (2006) In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52
Vassiliou V, Bruland O, Janjan N, et al. (2009) Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy:interactions and effectiveness. Clin Oncol (R Coll Radiol) 21:665–667
Wu JS, Wong R, Johnston M, et al. (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605
Wu JS, Monk G, Clark T, et al. (2006) Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases:a quality assurance study. Clin Oncol (R Coll Radiol) 18:539–544
Yu HH, Hoffe SE (2012) Beyond the conventional role of external-beam radiation therapy for skeletal metastases:new technologies and stereotactic directions. Cancer Control 19:129–136
Zeng L, Lutz S, Chow E, et al. (2012) Recent important developments in the management of nonspine bone metastases. Curr Opin Support Palliat Care 6:80–84
■Zu 17.2
Anderson PM, Wiseman GA, Dispenzieri A, et al. (2002) High-dose Samarium-153 ethylene diamine tetramethylene phosphophate:low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20:189–196
Anderson PM, Aguilera D, Pearson M, Shaio W (2008) Outpatient chemotherapy plus radiotherapy in sarcomas:improving cancer control with radiosensitizing agents. Cancer Control 15:38–46
Atkins HL, Mausner LF Srivastava SC, Meinken GE, et al. (1995) Tin- 117m(4+)-DTPA for palliation of pain from osseous metstases:a pilot study. J Nucl Med 36:725–729
Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer Suppl 72:3443–3451
Baczyk M, Czepczynski R, Milecki P, et al. (2007) 89Sr versus 153Sm- EDTMP:comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28:245–250
Banerjee SR, Pullambhatia M, et al. (2011) A modular strategy to prepare multivalent inhitors of prostate-specific membrane antigen (PSMA). Oncotarget 2:1244–1253
Baum RP, Kulkarni HR (2012) Theranostics:from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy –the Bad Berka experience. Theranostics 2:437–447
Baziotis N, Yakoumakis E, Zissimopoulos, et al. (1998) Strontium-89 chloride in the treatment of bone metatases from breast cancer. Oncology 55:377–381
Berger M, Grignani G, Giostra A, et al. (2012) 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 23:1899–1905
Blake GM, Zivanovic MA, McEwan AJB, Ackery DM (1986) Sr-89 therapy:strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454
Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ et al. (1993) Strontium- 89 (Metastron) versus external beam radiotherapy in patients with painful bone metatases secondary to prostate cancer:preliminary report of a multicente trial. Sem Oncol 20 (Suppl 2):32–33
Bouchet LG, Bolch WE, Goddu SM, et al. (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 41:682–687
Braun S, Vogl FD, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802
Brenner W, Kampen WU, Kampen AM, Henze E (2001) Skeletal uptake and soft tissue retention of 186-Re-HEDP and 153-Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 42:231–236
Brucer M (1990) A chronology of nuclear medicine. Heritage Publications, St. Louis
Christensen MH, Petersen LJ (2012) Radionulcide treatment of painful bone metastases in patients with breast cancer:a systematic review. Cancer Treat Rev 38:164–171
Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77:336–340
Deguchi T, Yang M, Ehara H et al. (1997) Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 75:634–638
deKlerk JMH (1995) Re-186-HEDP in treatment of metatatic bone disease:pharmakokinetics and toxocity. Ponson & Looigen, Wagenningen
Ducy P, Schinke T, Karsenty G (2000) The osteoblast:a sophisticated fibroblast under central surveillance. Science 289:1501–1504
Elgazzar AH, Maxon HR (1993) Radioisotope therapy of cancer related bone pain. In:Limouris GS, Shukla SK (eds) Radionuclides for therapy. Mediterra, Athen, pp 111–116
Fellner M, Baum RP, Kubícek V, Hermann P, Lukes I, Prasad V, Rösch F (2010) PET/CT imaging of osteoblastic bone metastases with (68) Ga-bisphosphonates:first human study. Eur J Nucl Med Mol Imaging 37:834
Fischer M (1999) Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 38:270–272
Fischer M, Böhme K (1996) Nuklearmedizinsche Schmerztherapie bei metastasiertem Prostatakarzinom. Nuklearmediziner 5:339–344
Fischer M, Kampen WU (2012a) Therapie mit offenen Radionukliden bei multilokulärer Skelettmetastasierung. Der Nuklearmediziner 35:186–191
Fischer M, Kampen WU (2012b) Radionucliude therapy of bone metastases. Breast Care 7:100–107
Fizazi K, Beuzeboc P, Lumbroso J et al. (2009) Phase II trial of consolidation Docetaxel and Samarium-153 in patients with bone metastases from castration-resistent prostate cancer. J Clin Oncol 27:1–7
Fuster D, Herranz R, Vidal-Sicart S, et al. (2000) Usefulness of strontium- 89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 21:623–626
Galasko CSB (1982) Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169:20–27
Geldof AA, de Rooij L, Versteegh RT, et al. (1999) Combination 186-Re- HEDP and cisplatin supraadditive treatment effects in prostate cancer cells. J Nucl Med 40:667–671
Gerlinger M, Rowan AJ, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequency. N Engl J Med 366:883–892
Goddu SM, Bbishayee A, Bouchet LG, et al. (2000) Marrow toxicity of 33-P versus 32-P-orthophosphate:implication for therapy of bone pain and bone metastases. J Nucl Med 41:941–951
Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH (2002) Significant antitumor effect from bone-seeking, α-particle-emitting 223-Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125
Hicsonmez A, Kucuk ON, Nadrieu MN, et al. (2010) Role of radionuclide therapy as adjuvant to palliative external beam radiotherapy for painful skeletal metastasis. World J Oncol 1:158–166
Hobbs R, McNutt T, et al. (2008) Combined internal radionuclide therapy (IRT) and external radiation therapy (XRT) treatment planning for 153Sm-EDTMP treatment of metastatic osteosarcoma. J Nucl Med 49 (Suppl 1):47P
Kalesnikov-Gauthier H, Carpenier P, Depreux P, et al. (2000) Evaluation of toxicity and efficacy of 186-Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41:1689–1694
Kasalický J, Kraská V (1998) The effect of repeated strontium-89 chloride therapy in bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25:1362–1367
Kohno N, Aogi K, Minami H, et al. 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized placebo-controlled trial. J Clin Oncol 23:3314–3321
Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT (1997) Diagnostic bone scanning in oncology. Semin Nucl Med 27:107–141
Krishnamurthy GT, Krishnamurthy S (2000) Invited commentary:Radionuclides for metastatic bone pain palliation:a need for rational re-evaluation in the new millenium. J Nucl Med 41:688–691
Lam MGEH, Dahmane A, Stevens WHM, et al. (2008) Combined use of zoledronic acid and 153 Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eu J Nucl Med Mol Imaging 35:756–765
Lam MGEH, de Klerk JMH, Zonnenberg BA (2009) Treatment of painful bone metastases in hormone- refractory prostate cancer with Zoledronic acid and Samarium-153-Ethylenediaminetetramethylphosphonic acid combined. J Pall Med 12:649–651
Lau WF, Hicks R, Binns D (2001) Differential effects of bisphosphonate on Paget´s disease and metastatic prostatic carcinoma bone scan findings. Clin Nucl Med 26:347–348
Liepe K, Franke W-G, Koch R, et al. (2000) Comparison of Rhenium-188, Rhenium-186 and Strontium-89 in palliation of painful bone metastases. Nuklearmedizin 39:146–151
Loeb DM, Garrett-Mayer G, Hobbs RF et al. (2009) Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 115:2514–2522)
Loeb DM, Hobbs RF, Okoli A, et al. (2011) Tandem dosing of Samarium- 153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer 116:5470–5478
Malmberg I, Persson U, Ask A, et al. (1997) Painful bone metastases in hormon-refractory prostate cancer:economic cost of strontium- 89 and/or external radiotherapy. Urology 50:747–753
Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, Diestelhorst S, Minami C (2002) Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm- 153-EDTMP. Clin Nucl Med 27:427–430
Mathé, D, Balogh L, Polyák A, et al. (2010) Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu- EDTMP, a potential bone pain palliation agent. Nucl Med Biol 73:215–226
Maxon HR, Deutsch EA, Thomas SR, Libson K (1988) Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone:human biodistribution and dosimetric studies. Radiology 166:501–507
McCready VR, O´Sullivan J, Dearnaly D, Cook G (2002) Prediction of response of skeletal metastases from cancer of the prostate to high activity 186-Re HEDP therapy. J Nucl Med 43 Suppl 316 (abstr.) McEwan AJB (1994) Palliation of bone pain. In:Murray IPC, Ell PJ (Hrsg) Nuclear medicine in clinical diagnosis and treatment. Churchill Livingston, Edinburgh, pp 877–892
McEwan AJB, et al. (1994) A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur J Urol 26, Suppl 1:26–31
Nilsson S, Larsen RH, Fossa SD, et al. (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451–4459
Nilsson S, Strang P, Aksnes AK, et al. (2012) A randomized, dose-response, multicenter phase II study of radium-223-chloride for the palliation of painful bone metastases in patients with castrationresistant prostate cancer. Eur J Cancer 48:678–686
Palmedo H, Manka-Waluch A, Albers P, et al. (2003). Repeated bonetargeted therapy for hormone-refractory prostate carcinoma:randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869–2875
Parker C, Nilsson S, Heinrich D, et al. (2012) Updated analysis of the phase III, double-blind, randomized, multinational study of radium- 223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases. J Clin Oncol 30 (Suppl) Abstr LBA4512
Parker CC, Pascoe S, Chodacki A, et al. (2013) A randomized, doubleblind, dose-finding, multicenter, phase II study od radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63:189–197
Paulus P (1995) Re-186-HEDP in routine use:correlation between dose rate measurements and clinical efficacy. Update 1:17–20
Pecher C (1942) Biological investigations with radioactive calcium and strontium:preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ California Publ Pharmacol 2:117–149
Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D, Setoain J (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24:1210–1214
Porter AT, McEwan AJB, Powe JE, Reid R, et al. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local external beam irradiation in the managemant of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 25:805–813
Roodman GD (1997) Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557–1514
Roqué i Figuls M, Martinez-Zapata MJ, Alonso-Coello P, et al. (2008) Radioisotopes for metastatic bone pain (review). The Cochrane Library 4:1–32
Rösch F, Baum RP (2011) Generator-based PET radiopharmaceuticals for molecular imaging of tumours:on the way to THERANOSTICS. Dalton Trans 40:6104–6111
Rosen LS, Gordon D, Kaminski M, et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer –a randomized, double-blind multicenter trial. Cancer 98:1735–1744.
Schäfer M, Bauder-Wüst U, et al. (2012) A dimerized urea-based inhibitor of the prostatie-specific membrane antigen for 68Ga-PET imaging of prostate cancer. Eur J Nucl Med Mol I 2:23
Schoeffel D, Bastian L, et al. (2010) Metastasen der Wirbelsäule –eine interdisziplinäre Herausforderung. J Onkol 7, Sonderdruck S1–6
Sciuto R, Tofani A, Festa A, et al. (2000) Short- and long-term effects of 186-Re-1,-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41:647–654
Sciuto R, Festa A, Rea S, et al. (2002) Effects of low-dose Cisplatin on 89-Sr therapy for painful bone metastases from prostate cancer:a randomized clinical trial. J Nucl Med 43:79–86
Serafini AN (2000) Samarium Sm-153 Lexidronam for the palliation of bone pain associated with metastases. Cancer 88 (Suppl) 2034–2039
Serafini AN (2001) Therapy of metstatic bone pain. J Nucl Med 42:895–906
Singh A, Holmes RA, Farhangi M, Volkert WA (1989) Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818
Sinzinger H, Palumbo B, Özker K (2011) The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imaging 55:420–430
Soerdjbalie-Maikoe V, Pelger RCM, Lycklama á Nijeholt GAB, et al. (2002) Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med 29:494–498
Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic cancer with low-dose prednisone:evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597
Tu SM, Delpass ES, Jones D, et al. (1997) Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer. Urol Oncol 2:191–197
Tu SM, Millikan RE, Mengistu B, et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomised phase II trial. Lancet 357:336–341
Valicenti RK, Trabulsi E, Intenzo C, et al. (2011) A phase I trial of samarium- 153-Lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer:first report of a complete study. IJROBP 79:732–737
Wagner G (1984) Frequency of pain in patients with cancer. Recent Results Cancer Res 89:64–71
Wood DP, Banks ER , Humphreys S, Rangnekar VM (1994) Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. Z Histochem Cytochem 42:505–511
World Health Organisation (1990) Cancer pain relief and palliative care. WHO Tech Rep Ser 804:7–73
Zyskowski A, Lamb D, Morum P, et al. (2001) Strontium-89 treatment for prostate cancer bone metastases:does a protate specific antigen response predict for improved survival? Aust Radiol 45:39–42
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Adamietz, I., Schmidberger, H., Kampen, W., Czech, N., Fischer, M. (2013). Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung. In: Baron, R., Koppert, W., Strumpf, M., Willweber-Strumpf, A. (eds) Praktische Schmerzmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37605-4_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-37605-4_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37604-7
Online ISBN: 978-3-642-37605-4
eBook Packages: Medicine (German Language)